A 36-week multicenter,randomized,double-blind,placebo-controlled,parallel-group,Phase 3 clinical tri

来源 :2019全国老年痴呆与认知障碍相关疾病学术大会 | 被引量 : 0次 | 上传用户:lnfssg
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  BACKGROUND New therapies are urgently needed for Alzheimer disease(AD).Sodium oligomannate(GV-971)is a marine-derived oligosaccharide that has been shown to decrease amyloid deposition,reduce neuroinflammation,reconstitute gut microbiota,and improve cognition in animal models of AD.
其他文献
  胰腺癌(PDAC)是一种恶性程度极高并迅速致命的难治性恶性肿瘤,目前,吉西他滨仍为治疗PDAC 的一线化疗药物。本研究力图通过基因型表型的关联分析研究以确定与预测性吉西
会议
会议
会议
  The unbalance between synaptic(GluN2A,mediating the protective pathway)and extra-synaptic NMDA receptors(NMDARs)(GluN2B,mediating the excitotoxic pathway)ha
  Leukemia stem cells(LSCs)insensitive to imatinib are believed to be responsible for resistance to BCR-ABL tyrosine kinase inhibitors and relapse of chronic
会议
  The emerging roles of microRNAs(miRs)have been deeply investigated in cancer.MiR-194 is deregulated in various cancers,whereas little is known about it in h
会议
  It has been demonstrated that inflammation and dysregulation of immune response are involved in the pathogenesis of Alzheimer disease(AD).
会议
会议
  OBJECTIVE Currently,almost all chemical compounds or biological reagents to reverse or slow down the AD process have failed in clinical trials.